These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. [Complications of portal hypertension in the liver cirrhosis]. Ivashkin VT Ross Fiziol Zh Im I M Sechenova; 2009 Oct; 95(10):1074-92. PubMed ID: 19957897 [TBL] [Abstract][Full Text] [Related]
66. The Pathophysiology of Portal Hypertension. Ramkissoon R; Cao S; Shah VH Clin Liver Dis; 2024 Aug; 28(3):369-381. PubMed ID: 38945632 [TBL] [Abstract][Full Text] [Related]
67. Liver fibrosis: a dynamic and potentially reversible process. Povero D; Busletta C; Novo E; di Bonzo LV; Cannito S; Paternostro C; Parola M Histol Histopathol; 2010 Aug; 25(8):1075-91. PubMed ID: 20552556 [TBL] [Abstract][Full Text] [Related]
69. Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis. Guido M; Sarcognato S; Russo FP; Cardin R; Piciocchi M; Colloredo G; Farinati F Liver Int; 2018 Oct; 38(10):1770-1776. PubMed ID: 29427537 [TBL] [Abstract][Full Text] [Related]
70. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Li H Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):217-233. PubMed ID: 33131349 [No Abstract] [Full Text] [Related]
71. [Aspects of pathogenetc pharmacotherapy for portal hypertension in liver cirrhosis]. Garbuzenko DV Ter Arkh; 2016; 88(2):101-108. PubMed ID: 27135108 [TBL] [Abstract][Full Text] [Related]
72. [Nitric oxide and hyperdynamic circulation in liver cirrhosis]. Wang Y; Gu C Zhonghua Nei Ke Za Zhi; 1995 Nov; 34(11):779-81. PubMed ID: 8731852 [No Abstract] [Full Text] [Related]
73. Hepatic stellate cells and intrahepatic modulation of portal pressure. Mallat A Digestion; 1998; 59(4):416-9. PubMed ID: 9693221 [No Abstract] [Full Text] [Related]
74. Statins and portal hypertension: A tale of two models. Arab JP; Shah VH Hepatology; 2016 Jun; 63(6):2044-7. PubMed ID: 27015447 [No Abstract] [Full Text] [Related]
75. Correlations between sinusoidal pressure and liver morphology in cirrhosis. Picchiotti R; Mingazzini PL; Scucchi L; Bressan M; Di Stefano D; Donnetti M; Feroci L J Hepatol; 1994 Mar; 20(3):364-9. PubMed ID: 8014448 [TBL] [Abstract][Full Text] [Related]
76. Endothelin and other mediators in the pathophysiology of portal hypertension. Gerbes AL; Gülberg V; Bilzer M Digestion; 1998 Jul; 59 Suppl 2():8-10. PubMed ID: 9718411 [No Abstract] [Full Text] [Related]
77. The relationship between the morphology of nucleus of liver cells and the liver functions and prognosis of portal hypertension due to hepatic cirrhosis. Peng ZH; Tang HM; Ma KZ; Dai ZB J Tongji Med Univ; 1995; 15(2):104-7. PubMed ID: 8731963 [TBL] [Abstract][Full Text] [Related]
78. [The role of activated hepatic stellate cells in liver fibrosis, portal hypertension and cancer angiogenesis]. Lee JS; Kim JH Korean J Hepatol; 2007 Sep; 13(3):309-19. PubMed ID: 17898548 [TBL] [Abstract][Full Text] [Related]
79. Hepatic fibrogenesis: from within and outwith. Henderson NC; Forbes SJ Toxicology; 2008 Dec; 254(3):130-5. PubMed ID: 18824072 [TBL] [Abstract][Full Text] [Related]
80. Vascular biology and pathobiology of the liver: Report of a single-topic symposium. Iwakiri Y; Grisham M; Shah V Hepatology; 2008 May; 47(5):1754-63. PubMed ID: 18393322 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]